What's breaking now, across thousands of outlets.
The FDA approved Elevar Therapeutics’ Lyrfigtu as a second-line treatment option for certain patients with bile duct cancer, which is diagnosed in about 8,000 Americans each year. Wednesday's green light for Lyrfigtu was based on ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Pixel Watch's new Health Guardian feature brings BP, insulin resistance, and sleep quality trends.
A new study led by UCLA Health found that a large percentage of disadvantaged patients are not taking their diabetes medications consistently.
Older Americans are increasingly taking multiple prescription medications and dietary supplements. Although the prevalence of potentially major drug-drug interactions has declined slightly, more than…
Novo Holdings, a leading global healthcare and life sciences investor, today announced a strategic minority ...
The proposed Food Safety and Standards (Prohibition and Restrictions on Sales) Amendment Regulations, 2026 seek to insert a new clause under Regulation 2.1.1 of the existing regulations, specifically…
Dannevirke locals have echoed calls from other towns in the Tararua region for a return to a local ownership model of healthcare.
